OTCMKTS:IMUC

ImmunoCellular Therapeutics Competitors

$0.51
+0.03 (+6.23 %)
(As of 04/14/2021 03:44 PM ET)
Add
Compare
Today's Range
$0.39
Now: $0.51
$0.51
50-Day Range
$0.37
MA: $0.65
$0.87
52-Week Range
$0.06
Now: $0.51
$0.98
Volume864 shs
Average Volume23,552 shs
Market Capitalization$1.80 million
P/E RatioN/A
Dividend YieldN/A
Beta1.61

Competitors

ImmunoCellular Therapeutics (OTCMKTS:IMUC) Vs. WCUI, KAYS, ISCO, IPCIF, BCTXF, and FWDG

Should you be buying IMUC stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to ImmunoCellular Therapeutics, including Wellness Center USA (WCUI), Kaya (KAYS), International Stem Cell (ISCO), Intellipharmaceutics International (IPCIF), BriaCell Therapeutics (BCTXF), and FutureWorld (FWDG).

Wellness Center USA (OTCMKTS:WCUI) and ImmunoCellular Therapeutics (OTCMKTS:IMUC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Insider & Institutional Ownership

0.1% of Wellness Center USA shares are held by institutional investors. 14.1% of Wellness Center USA shares are held by insiders. Comparatively, 3.3% of ImmunoCellular Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Wellness Center USA and ImmunoCellular Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Wellness Center USA$30,000.00228.21$-2,390,000.00N/AN/A
ImmunoCellular TherapeuticsN/AN/AN/AN/AN/A

ImmunoCellular Therapeutics has lower revenue, but higher earnings than Wellness Center USA.

Volatility & Risk

Wellness Center USA has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, ImmunoCellular Therapeutics has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Wellness Center USA and ImmunoCellular Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Wellness Center USA0000N/A
ImmunoCellular Therapeutics0000N/A

Profitability

This table compares Wellness Center USA and ImmunoCellular Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Wellness Center USAN/AN/A-1,809.19%
ImmunoCellular TherapeuticsN/AN/AN/A

Summary

Wellness Center USA beats ImmunoCellular Therapeutics on 3 of the 5 factors compared between the two stocks.

ImmunoCellular Therapeutics (OTCMKTS:IMUC) and Kaya (OTCMKTS:KAYS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.

Profitability

This table compares ImmunoCellular Therapeutics and Kaya's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunoCellular TherapeuticsN/AN/AN/A
Kaya-1,558.07%N/A-586.93%

Earnings and Valuation

This table compares ImmunoCellular Therapeutics and Kaya's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunoCellular TherapeuticsN/AN/AN/AN/AN/A
Kaya$1.01 million6.17$7.80 millionN/AN/A

Kaya has higher revenue and earnings than ImmunoCellular Therapeutics.

Analyst Recommendations

This is a breakdown of current ratings for ImmunoCellular Therapeutics and Kaya, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunoCellular Therapeutics0000N/A
Kaya01002.00

Volatility and Risk

ImmunoCellular Therapeutics has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Comparatively, Kaya has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500.

Summary

ImmunoCellular Therapeutics beats Kaya on 3 of the 4 factors compared between the two stocks.

International Stem Cell (OTCMKTS:ISCO) and ImmunoCellular Therapeutics (OTCMKTS:IMUC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Valuation & Earnings

This table compares International Stem Cell and ImmunoCellular Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
International Stem Cell$9.47 million0.57$-4,260,000.00N/AN/A
ImmunoCellular TherapeuticsN/AN/AN/AN/AN/A

ImmunoCellular Therapeutics has lower revenue, but higher earnings than International Stem Cell.

Volatility & Risk

International Stem Cell has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, ImmunoCellular Therapeutics has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for International Stem Cell and ImmunoCellular Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
International Stem Cell0000N/A
ImmunoCellular Therapeutics0000N/A

Profitability

This table compares International Stem Cell and ImmunoCellular Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
International Stem Cell-55.56%N/A-72.21%
ImmunoCellular TherapeuticsN/AN/AN/A

Summary

ImmunoCellular Therapeutics beats International Stem Cell on 3 of the 4 factors compared between the two stocks.

ImmunoCellular Therapeutics (OTCMKTS:IMUC) and Intellipharmaceutics International (OTCMKTS:IPCIF) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Valuation and Earnings

This table compares ImmunoCellular Therapeutics and Intellipharmaceutics International's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunoCellular TherapeuticsN/AN/AN/AN/AN/A
Intellipharmaceutics International$3.48 million1.57$-8,090,000.00N/AN/A

ImmunoCellular Therapeutics has higher earnings, but lower revenue than Intellipharmaceutics International.

Analyst Recommendations

This is a summary of current ratings for ImmunoCellular Therapeutics and Intellipharmaceutics International, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunoCellular Therapeutics0000N/A
Intellipharmaceutics International0000N/A

Volatility and Risk

ImmunoCellular Therapeutics has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500. Comparatively, Intellipharmaceutics International has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500.

Profitability

This table compares ImmunoCellular Therapeutics and Intellipharmaceutics International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunoCellular TherapeuticsN/AN/AN/A
Intellipharmaceutics International-232.11%N/A-81.71%

Summary

ImmunoCellular Therapeutics beats Intellipharmaceutics International on 3 of the 4 factors compared between the two stocks.

BriaCell Therapeutics (OTCMKTS:BCTXF) and ImmunoCellular Therapeutics (OTCMKTS:IMUC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, dividends, profitability and analyst recommendations.

Risk & Volatility

BriaCell Therapeutics has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Comparatively, ImmunoCellular Therapeutics has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500.

Insider & Institutional Ownership

0.1% of BriaCell Therapeutics shares are held by institutional investors. 3.3% of ImmunoCellular Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares BriaCell Therapeutics and ImmunoCellular Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BriaCell TherapeuticsN/AN/A-786.77%
ImmunoCellular TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for BriaCell Therapeutics and ImmunoCellular Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BriaCell Therapeutics0000N/A
ImmunoCellular Therapeutics0000N/A

Valuation and Earnings

This table compares BriaCell Therapeutics and ImmunoCellular Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A$-3,680,000.00N/AN/A
ImmunoCellular TherapeuticsN/AN/AN/AN/AN/A

Summary

ImmunoCellular Therapeutics beats BriaCell Therapeutics on 3 of the 4 factors compared between the two stocks.

FutureWorld (OTCMKTS:FWDG) and ImmunoCellular Therapeutics (OTCMKTS:IMUC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability.

Profitability

This table compares FutureWorld and ImmunoCellular Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
FutureWorldN/AN/AN/A
ImmunoCellular TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a breakdown of current recommendations for FutureWorld and ImmunoCellular Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
FutureWorld0000N/A
ImmunoCellular Therapeutics0000N/A

Risk and Volatility

FutureWorld has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, ImmunoCellular Therapeutics has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500.

Earnings and Valuation

This table compares FutureWorld and ImmunoCellular Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FutureWorldN/AN/AN/AN/AN/A
ImmunoCellular TherapeuticsN/AN/AN/AN/AN/A

Summary

ImmunoCellular Therapeutics beats FutureWorld on 1 of the 1 factors compared between the two stocks.


ImmunoCellular Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Wellness Center USA logo
WCUI
Wellness Center USA
0.5$0.06+6.7%$6.39 million$30,000.000.00Gap Down
KAYS
Kaya
0.7$0.43+0.0%$6.23 million$1.01 million0.00Gap Up
International Stem Cell logo
ISCO
International Stem Cell
0.8$0.72+4.2%$5.65 million$9.47 million0.00Gap Down
Intellipharmaceutics International logo
IPCIF
Intellipharmaceutics International
0.6$0.23+4.8%$5.19 million$3.48 million-1.92News Coverage
Gap Up
BCTXF
BriaCell Therapeutics
0.0N/AN/A$4.59 millionN/A-0.01
FutureWorld logo
FWDG
FutureWorld
0.5$0.00+16.7%$4.56 millionN/A0.00Gap Down
American Bio Medica logo
ABMC
American Bio Medica
0.5$0.11+4.3%$4.49 million$3.65 million0.00Decrease in Short Interest
AMBS
Amarantus BioScience
0.0$0.01+1.8%$4.13 millionN/A0.00Increase in Short Interest
Gap Up
AKRXQ
Akorn
0.1$0.03+0.0%$3.60 million$682.43 million-0.01
VG Life Sciences logo
VGLS
VG Life Sciences
0.0$0.01+1.3%$3.45 millionN/A0.00Increase in Short Interest
News Coverage
Gap Up
Immune Pharmaceuticals logo
IMNPQ
Immune Pharmaceuticals
0.0$0.17+15.2%$2.94 millionN/A0.00High Trading Volume
Increase in Short Interest
News Coverage
Gap Down
INNVD
Innovus Pharmaceuticals
0.6N/AN/A$2.90 million$23.99 million-0.72Gap Down
RSPI
RespireRx Pharmaceuticals
0.5$0.04+0.0%$2.84 millionN/A-0.09
NSPX
Inspyr Therapeutics
0.5$0.02+0.0%$2.31 millionN/A0.00Gap Down
Boston Therapeutics logo
BTHE
Boston Therapeutics
0.5$0.02+0.0%$2.16 million$20,000.00-0.97
VVUSQ
VIVUS
0.6$0.12+0.0%$2.10 million$69.76 million-0.04
IMUCD
ImmunoCellular Therapeutics
0.0$0.48+6.2%$2.01 millionN/A0.00
Capstone Therapeutics logo
CAPS
Capstone Therapeutics
0.8$36.01+5.6%$1.95 million$2 million0.00High Trading Volume
Gap Down
WWHC
W World
0.8$6.09+0.0%$1.80 millionN/A0.00Increase in Short Interest
News Coverage
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.03+21.6%$1.70 million$530,000.000.00Gap Down
Cardax logo
CDXI
Cardax
0.0$2.00+5.0%$1.67 million$710,000.000.00
MLNTQ
Melinta Therapeutics
0.2$0.11+0.0%$1.51 million$96.43 million0.00
Achaogen logo
AKAOQ
Achaogen
0.6$0.03+0.4%$1.31 million$8.73 million0.00Gap Up
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.05+0.0%$1.12 millionN/A-0.57Decrease in Short Interest
News Coverage
Gap Down
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.04+19.7%$1.11 millionN/A0.00Gap Up
AOXG
Aoxing Pharmaceutical
0.5$0.02+10.4%$1.05 millionN/A0.00Gap Up
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.21+4.8%$1.03 millionN/A0.00Decrease in Short Interest
Gap Up
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07+2.1%$970,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
SPHS
Sophiris Bio
0.1$0.03+0.0%$965,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
AOLS
Aeolus Pharmaceuticals
0.8$0.01+12.9%$928,000.00N/A0.00Increase in Short Interest
News Coverage
ATRX
Adhera Therapeutics
0.0$0.08+0.0%$872,000.00$250,000.000.00
Spotlight Innovation logo
STLT
Spotlight Innovation
0.5$0.01+125.0%$772,000.00N/A0.00Gap Up
Sienna Biopharmaceuticals logo
SNNAQ
Sienna Biopharmaceuticals
0.5$0.02+36.3%$749,000.00N/A0.00News Coverage
Gap Up
PXYN
Praxsyn
0.6$0.00+20.0%$678,000.00N/A0.00Increase in Short Interest
Gap Down
SKVI
Skinvisible
0.7$0.15+0.0%$671,000.00$40,000.000.00
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05+0.0%$572,000.00$1.90 million0.00
TRPXD
Therapix Biosciences
0.0$9.15+1.0%$458,000.00N/A0.00High Trading Volume
BSPM
Biostar Pharmaceuticals
0.0$0.17+0.0%$436,000.00N/A0.00
HSTC
HST Global
0.8$0.07+0.0%$378,000.00N/A0.00
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47+3.7%$338,000.00$36.55 million0.00News Coverage
Gap Up
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.01+0.0%$319,000.00N/A0.00Increase in Short Interest
Gap Down
PZRXQ
PhaseRx
0.2$0.03+0.0%$298,000.00N/A0.00Decrease in Short Interest
News Coverage
WDBG
Woodbrook Group
0.0$1.60+0.0%$224,000.00N/A0.00
ROSGQ
Rosetta Genomics
0.0$0.09+5.9%$124,000.00N/A0.00Gap Up
MetaStat logo
MTST
MetaStat
0.0$0.02+0.0%$118,000.00$20,000.000.00
OREXQ
Orexigen Therapeutics
0.4$0.01+26.4%$100,000.00$33.71 million0.00Gap Up
AXMP
AXM Pharma
0.2$0.00+0.0%$81,000.00N/A0.00
ALSE
Alseres Pharmaceuticals
0.0$6.00+0.0%$36,000.00N/A0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00+0.0%$20,000.00N/A0.00
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$0.02+13.2%$9,000.00$110,000.000.00Decrease in Short Interest
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.